Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Revenue for 6 consecutive years, with $143000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 25.91% year-over-year to $143000.0, compared with a TTM value of $632000.0 through Sep 2025, up 66.75%, and an annual FY2024 reading of $15.0 million, up 1766.46% over the prior year.
  • Revenue was $143000.0 for Q3 2025 at Barinthus Biotherapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Revenue topped out at $17.1 million in Q2 2022 and bottomed at -$7000.0 in Q4 2023.
  • Average Revenue over 5 years is $2.9 million, with a median of $193000.0 recorded in 2024.
  • The sharpest move saw Revenue plummeted 100.28% in 2021, then surged 645800.0% in 2022.
  • Year by year, Revenue stood at -$1000.0 in 2021, then soared by 645800.0% to $6.5 million in 2022, then plummeted by 100.11% to -$7000.0 in 2023, then skyrocketed by 2557.14% to $172000.0 in 2024, then fell by 16.86% to $143000.0 in 2025.
  • Business Quant data shows Revenue for BRNS at $143000.0 in Q3 2025, $1000.0 in Q2 2025, and $316000.0 in Q1 2025.